Full-Time

Executive Director

Clinical Development

Posted on 5/21/2025

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$362k - $416k/yr

San Carlos, CA, USA

Hybrid

This position is hybrid, requiring some in-office presence at the headquarters in Redwood City, CA.

Category
🩺Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • MD, PhD or similar biomedical graduate degree with 8 or more years experience in pharmaceutical/biotech industry.
  • Extensive experience working with the principles and techniques of data analysis, interpretation, and clinical relevance as related to the pharmaceutical/biotech industry.
  • Proven track record of successfully designing and conducting multiple clinical trials as part of a wider clinical development programs from early-stage to late-stage, direct experience with Phase 1 drug development.
  • Experience authoring and clinical development strategy(ies) and bringing forward for governance.
  • Extensive understanding of medical aspects of GCP (Good Clinical Practice), ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use), FDA, EMA, and other relevant guidelines and regulations.
  • Proven experience to steer an IMP during its clinical development plan through major and varied Health Authority interactions (e.g. FDA, EMA, others). Has led Health Authority interaction(s)
  • Strong orientation to teamwork. Excellent leadership, communication, and interpersonal skills, with the ability to inspire, motivate and mentor a diverse team.
  • Expertise in building and maintaining strong relationships with internal and external stakeholders.
  • Superb strategic thinking and analytical skills, with the ability to make data-driven decisions in a fast-paced environment. Able to recognize trade-off decisions and can determine priorities and goals.
  • Outstanding written and business presentation skills. Experience publishing results of a clinical trial in a peer-reviewed journal is required.
  • Proven ability to manage budgets and timelines effectively.
  • Passion for innovation and a commitment to developing therapies that make a meaningful difference in patients' lives.
Responsibilities
  • Provide critical insights/contributions and implement comprehensive/execute upon the clinical development plans for Revolution Medicines’ molecules, ensuring alignment with scientific, regulatory, and commercial objectives.
  • Lead, mentor, and manage a high-performing cross-functional team of clinical development professionals, fostering a culture of collaboration, innovation, and excellence.
  • Oversee all aspects of clinical trial design and execution, including site selection, patient recruitment, data management, and regulatory compliance.
  • Establish and maintain strong relationships with clinical investigators, regulatory agencies, and key stakeholders.
  • Gather, analyze and interpret clinical data, providing strategic insights to inform critical decisions and guide program development.
  • Manage clinical development timelines effectively, ensuring efficient resource allocation and achievement of milestones.
  • Stay abreast of the latest scientific advancements and regulatory trends in the field of clinical development.
  • Partner with cross-functional teams, including research, regulatory affairs, commercial, and finance, to ensure seamless program execution and achieve shared goals.
  • Manage multiple direct reports; potentially be a manager of managers.
Desired Qualifications
  • Experience in ongoing enhancements/development of core and sub-team processes, structures, systems, tools and other resources in the pharmaceutical/biotech industry.
  • Experience creating clinical development strategy(ies) that led to label-enabling outcomes and commercialization.
  • Experience submitting an NDA/BLA/MAA to global health authorities is a significant plus.
  • Has led regulatory and other internal partners/stakeholders in the completion and submission of regulatory documentation. Successfully provided clinical science information and input for regulatory development of label(s) and packaging language, etc.
  • Has led or overseen data generation to address unmet medical needs and identify new or extended Clinical Development studies for the assigned program or other programs.
  • Direct experience with Phase IV drug development.
  • Has proven abilities to present [a] compelling business case and facilitates effective and expeditious decision-making. Has demonstrated the ability to serve as a company spokesperson both internally and externally.
  • Has demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. - resulting in demonstrable outcomes (e.g. new study proposals or new disease indications).
  • Has demonstrated courage and conviction in past positions and responsibilities. Skilled in conflict resolution.

Revolution Medicines focuses on developing treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines targets a niche market of RAS-driven cancers, working closely with healthcare providers and institutions to bring their therapies to patients. Their goal is to transform cancer treatment by providing effective, targeted therapies for patients suffering from these challenging cancers.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $2 billion capital raise supports global expansion and commercialization strategies.
  • Acquisition of EQRx enhances market reach and competitive positioning.
  • Recognition for transformative pancreatic cancer research highlights leadership in oncology.

What critics are saying

  • EQRx acquisition may dilute focus on high-value cancer therapies.
  • Independent global strategy could strain resources and delay market entry.
  • $750 million debt facility increases financial risk if commercialization fails.

What makes Revolution Medicines unique

  • Revolution Medicines synthesizes pharmaceutically optimized analogues of complex natural products.
  • Their Tri Complex Inhibitor platform creates highly specialized cancer treatments.
  • Focus on RAS gene mutations addresses critical unmet medical needs in oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -1%

2 year growth

↓ -2%
MarketScreener
Jun 24th, 2025
Revolution Medicines, Inc Announces Debt Facility Up to $750 Million Senior Secured Term Loan

Revolution Medicines, Inc. announced that the debt facility up to $750 million senior secured term loan consisting of three $250 million tranches linked to commercialization of daraxonrasib. The...

BioWorld
Jun 24th, 2025
Revmed secures $2B for global expansion

Revolution Medicines (Revmed) has secured $2 billion in capital to develop its own global commercial infrastructure for RAS(ON) inhibitors, targeting RAS-addicted cancers. The company decided to independently manage its global development and commercial strategies, rather than partnering outside the U.S. as initially planned, according to CEO Mark Goldsmith.

BioWorld
Jun 24th, 2025
Revmed goes global with $2B in capital for RAS(ON) inhibitors

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial infrastructure, instead of partnering outside the U.S. as it had originally intended.

PRWeb
May 9th, 2025
The Lustgarten Foundation Honors Revolution Medicines For Transformative Research In Pancreatic Cancer

"Revolution Medicines exemplifies the power of bold science and collaboration in driving meaningful progress for patients," said Linda Tantawi, CEO of the Lustgarten Foundation

Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

INACTIVE